We are live on ! Find out more

ADAG

Adagene

ADAG

Market cap $200M

2.98 USD

+0.01

0.34%

At close Updated Sep 24, 4:00 PM EDT

Pre-market

After hours

3.03

+0.05

1.68%

1 day

0.34%

5 days

-11.57%

1 month

-23.59%

3 months

-29.88%

6 months

-17.45%

Year to date

61.96%

1 year

46.8%

5 years

-79.03%

10 years

-90.06%

About: Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Employees: 128

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene's proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-4, anti-PD-1 or anti-CD137 antibodies SAN DIEGO and SUZHOU, China, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that China's National Medical Products Administration (NMPA) has approved the company's investigational new drug (IND) application for ADG138, a double-masked HER2×CD3 bispecific T cell engager built on Adagene's proprietary SAFEbody® precision masking technology.

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Adagene to Participate in Three Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York. 2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026 Format: 1x1 Meetings Date/Time: September 11, 2026 Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026 Format: Fireside Chat and 1x1 Meetings Fireside Chat Date/Time: September 15, 2026, 10:45–11:20 AM (Eastern Time) H.C.

Adagene to Participate in Three Upcoming Investor Conferences

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Zacks Investment Research

Adagene (ADAG) Upgraded to Buy: Here's What You Should Know

Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adagene (ADAG) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Are Medical Stocks Lagging Adagene (ADAG) This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Adagene (ADAG) This Year?

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company's focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

Adagene to Participate in Two Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.

Adagene to Participate in Two Upcoming Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™